Pharmaceuticals, Biotechnology and Life Sciences
Valeant Pharmaceuticals`s subsidiary, Bausch + Lomb, and Nicox have resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for latanoprostene bunod ophthalmic solution, 0.024%.
Canada-based drugmaker Valeant Pharmaceuticals was put in focus for an online stock market analyist among several other healthcare companies. Valeant and EyeGate inked a deal for worldwide commercial and manufacturing rights to a product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients.
The U.S. Food and Drug Administration (FDA) has approved Valeant Pharmaceuticals’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis.